Bronchial hyperresponsiveness in an adult population in Helsinki: decreased FEV₁, the main determinant

Maria Juusela¹, Paula Pallasaho², Seppo Sarna³, Päivi Piirilä¹, Bo Lundbäck⁴ and Anssi Sovijärvi¹

¹ Department of Clinical Physiology and Nuclear Medicine, Laboratory of Clinical Physiology, Helsinki University Hospitals, Helsinki, Finland
² Control of Hypersensitivity Diseases, Finnish Institute of Occupational Health, Helsinki, Finland
³ Department of Public Health, Helsinki University, Helsinki, Finland
⁴ Krefting Research Centre, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Abstract

Introduction: Bronchial hyperresponsiveness (BHR) elevates the risk for development of respiratory symptoms and accelerates the decline in forced expiratory volume in the first second (FEV₁). We thus aimed to assess the prevalence, determinants and quantity of BHR in Helsinki.

Objectives: This study involved 292 randomly selected subjects age 26–66 years, women comprising 58%.

Methods: Following a structured interview, a spirometry, a bronchodilation test, and a skin-prick test, we assessed a bronchial challenge test with inhaled histamine using a dosimetric tidal breathing method. Results included the provocative dose inducing a decrease in FEV₁ by 15% (PD₁₅FEV₁) and the dose-response slope. For statistical risk factor-analyses, the severity of BHR was considered; PD₁₅ values ≤1.6 mg (BHR) and ≤0.4 mg [moderate or severe BHR (BHRms)] served as cut-off levels.

Results: BHR presented in 21.2% and BHRms in 6.2% of the subjects. FEV₁ < 80% of predicted [odds ratio (OR) 4.09], airway obstruction (FEV₁/forced vital capacity < 88% of predicted) (OR 4.33) and history of respiratory infection at age < 5 (OR 2.65) yielded an increased risk for BHR as ORs in multivariate analysis. For BHRms, the determinants were decreased FEV₁ below 80% of predicted (OR 27.18) and airway obstruction (OR 6.16). Respiratory symptoms and asthma medication showed a significant association with BHR.

Conclusions: Of the adult population of Helsinki, 21% showed BHR to inhaled histamine. The main determinants were decreased FEV₁ and airway obstruction. Quantitative assessment of BHR by different cut-off levels provides a tool for characterization of phenotypes of airway disorders in epidemiologic and clinical studies.

Key words
bronchial hyperresponsiveness – histamine – respiratory symptoms – sensitization

Correspondence
Maria Juusela, MD, Helsinki University Central Hospital, Meilahti Hospitals, HUSLAB, Department of Clinical Physiology and Nuclear Medicine, BP 340, 00029 HUS, Finland.
Tel: +358 40 7461526
Fax: +358 9310 67111
email: maria.juusela@helsinki.fi

Received: 01 June 2011
Revision requested: 15 November 2011
Accepted: 14 December 2011
DOI:10.1111/j.1752-699X.2012.00279.x

Authorship
Principal author, M.J., performed the research, collected and analyzed the data, and wrote the paper. A.S. suggested the topic of the study, and supervised the research and writing of the paper. All the other authors contributed to the design of the study, the interpretation of results, and the revision of the manuscript.

Ethics
The Helsinki University Central Hospital Ethics Committee approved the study, with all patients giving written informed consent.

Conflict of interest
The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
Introduction
Bronchial hyperresponsiveness (BHR), a measure of functional airway disturbance in asthma, is a common consideration in epidemiologic studies (1–5). In Finland, the prevalence of physician-diagnosed asthma in adults has increased to 7% (6, 7), but epidemiologic data on BHR and its associations are available only from a selected study cohort from near the Arctic Circle (8).

A typical sign of asthma is inducible airway obstruction. BHR is associated with inflammation of the airways (9), geometric changes in the airway-tree (10, 11), heterogeneity of ventilation (12, 13) and ventilation-perfusion mismatch in the lungs (14), which links these research findings to asthma and bronchial provocation tests. Smoking (15, 16), obesity (17) and aging (18) are involved in an abnormal decline in ventilatory function and in BHR. Because recent epidemiologic studies have concluded that increased airway responsiveness is associated with an enhanced risk for respiratory symptoms and accelerated decline in forced expiratory volume in the first second (FEV₁) (19, 20), we aimed to assess the magnitude of BHR in an adult population and the determinants of BHR of different magnitudes. BHR has not previously been assessed by precise methods (21) in a general population, with risk factor analysis for different provocative dose inducing a decrease in FEV₁ by 15% (PD₁₅FEV₁) cut-off levels. Seldom are factors such as health history, allergic sensitization and lung-function measurements included in multivariate analysis for assessment of the determinants of BHR, as here (19, 20, 22).

Our aim was to determine the prevalence of BHR in a general adult population in Helsinki and to assess the determinants of increased BHR in general (BHR) and of moderate or severe BHR (BHRms) in relation to asthma, airway obstruction, ventilatory function, respiratory symptoms, smoking and allergic sensitization, with data from structured questionnaires, flow-volume spirometry studies and skin-prick tests (SPTs). The present study is a part of the epidemiologic (FinEsS) study in which in a longitudinal setting, follow-up studies have been in progress in Finland, Estonia and Sweden since 1996.

Materials and methods
Study cohort and subjects
The study involved 292 randomly selected subjects who had taken part in an initial postal questionnaire survey in Helsinki in 1996 (6). Fig. 1 illustrates the flow chart of the study cohort.

Of those who responded, a randomly selected sample of 1200 subjects was invited to the clinical studies in 2001–2003 (23). Of those 1200, for 600 subjects, the protocol included a histamine challenge test. The final participation rate for the present study was 45% (n = 292). The Helsinki University Central Hospital Ethics Committee approved the study, with all patients giving written informed consent.

The age range was 26–66 years (women 58%), mean 47. The baseline FEV₁ of those studied ranged from 62% to 129% of predicted (Finnish population values) (24). For 32 subjects (11%), FEV₁ was below the lower
normal limit (of the predicted <80%), and for 37 (13%), FEV1/forced vital capacity (FVC) was below normal (<88% of predicted). See demographic data in Tables 1 and 2.

The representativeness of the present study cohort was compared with that of the original study cohort of FinEsS I postal survey by gender and age, and use of the replies to the postal questionnaire (6). In the present study cohort, physician-diagnosed chronic bronchitis and symptoms related to chronic bronchitis were less frequently reported than in the original study cohort (FinEsS part I). The prevalences of reported respiratory symptoms, symptoms of allergic rhinoconjunctivitis (ARC), physician-diagnosed asthma and smoking were alike.

Clinical visits

The BHR challenge test was carried out within 14 days after the initial clinical visit. Of those 310 subjects who participated and were assigned according to the protocol for the bronchial provocation test, 18 subjects did not fulfill inclusion criteria for the baseline FEV1.

Among 83 subjects (28%), the histamine challenge test was performed during the period April to June during the main Finnish pollen season. The clinic visit included a structured interview, flow-volume spirometry with bronchodilation test and SPTs. The interview was held by a physician, and spirometry and the SPTs were performed by a trained nurse.

The interview comprised 162 questions on respiratory symptoms, family history of asthma and allergy, living conditions, occupation, and smoking habits (25, 26).

SPTs were performed in subjects <61 years old with allergen extracts for two controls (positive control, histamine 10 mg/mL and negative control, glycerin solvent) and 15 allergens (cat, dog, cow, horse, birch, timothy, mugworth, Alternaria alternata, Cladosporium herbarum, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Acarus siro, Lepidoglyphus destructor, cockroach, latex) (27). The decision as to

Table 1. Demographic data of the study population with completed histamine tests; values are given as mean ± standard deviation and range (n = 292). Forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) values were obtained from 291 subjects. Predicted values according to Viljanen et al. (24)

|                      | Men (n = 123) | Women (n = 169) | Total (n = 292) |
|----------------------|--------------|----------------|-----------------|
| Age (years)          | 45.2 ± 9.5 (28–65) | 47.3 ± 10.6 (26–66) | 46.4 ± 10.2 (26–66) |
| Height (m)           | 1.74 ± 0.06 (1.61–1.86) | 1.63 ± 0.07 (1.46–1.74) | 1.69 ± 0.08 (1.46–1.86) |
| Weight (kg)          | 80.0 ± 12.6 (43–110) | 70.6 ± 13.8 (48–105) | 75.6 ± 14.0 (43–110) |
| Body mass index      | 26.50 ± 4.37 (17.90–44.87) | 25.98 ± 6.04 (17.10–55.13) | 26.20 ± 5.40 (17.10–55.13) |
| FEV1 (L)             | 4.06 ± 0.70 (2.35–5.90) | 2.87 ± 0.51 (1.71–4.50) | 3.37 ± 0.84 (1.71–5.90) |
| FEV1 of predicted (%)| 94 ± 12 (62–127) | 94 ± 12 (71–129) | 94 ± 12 (62–129) |
| FVC (L)              | 5.28 ± 0.82 (3.09–8.03) | 3.65 ± 0.61 (2.15–5.39) | 4.34 ± 1.07 (2.15–8.03) |
| FVC of predicted (%) | 99 ± 11 (67–127) | 99 ± 12 (72–145) | 99 ± 12 (67–145) |
| FEV1/FVC of predicted (%) | 0.77 ± 0.06 (0.57–0.94) | 0.79 ± 0.06 (0.64–0.93) | 0.78 ± 0.06 (0.57–0.94) |
| Bronchodilatation from baseline, ΔFEV1 (%) | 3.1 ± 3.5 (4–21) | 2.0 ± 2.9 (5–15) | 2.4 ± 3.2 (5–21) |

Table 2. Smoking, allergic sensitization, respiratory symptoms and asthma, n = 292. Figures indicate numbers of subjects and their percentage in the groups.

|                      | Men (n = 123) | Women (n = 169) | Total (n = 292) |
|----------------------|--------------|----------------|-----------------|
| Non-smokers, n (%)   | 47 (38.2) | 74 (43.8) | 121 (41.4) |
| Ever-smokers, n (%)  | 76 (61.8) | 95 (56.2) | 171 (58.6) |
| 1 positive SPT reaction, n (%) | 55 (50.0) | 63 (44.7) | 118 (47.0) |
| ≥6 positive SPT reactions, n (%) | 10 (9.1) | 5 (3.5) | 15 (6.0) |
| Allergic rhinoconjunctivitis (ARC), n (%) | 40 (32.5) | 71 (42.0) | 111 (38.0) |
| Family history of asthma, n (%) | 17 (13.8) | 36 (21.3) | 53 (18.2) |
| Physician-diagnosed asthma, n (%) | 7 (5.7) | 6 (3.6) | 13 (4.5) |
| Asthma medication ever, n (%) | 21 (17.1) | 31 (18.3) | 52 (17.8) |
| Asthma medication past 12 months, n (%) | 9 (7.3) | 13 (7.7) | 22 (7.5) |

Skin-prick tests (SPTs) were performed for men (n = 110) and women (n = 141) <61 years (n = 251).
the age limit for SPTs was based on earlier data on decreased skin reactivity in later adult life (28).

Subjects underwent flow-volume spirometry with a Vmax22Spirometer (SensorMedics, Yorba Linda, CA, USA) according to 1994 American Thoracic Society criteria (29), wearing nose clips. We measured bronchodilatation response after their inhalation of salbutamol aerosol (0.4 mg) via a spacer (Ventoline®; GlaxoSmithKline, Brentford, UK). We recorded the largest FEV₁ and FVC from at least three acceptable curves.

Inclusion criteria for the BHR tests were a pretest value of FEV₁ ≥ 60% of predicted or ≥1.5 L, no respiratory infection within 4 weeks prior to the tests, no severe heart diseases (myocardial infarction within 3 months, unstable coronary disease, dysfunction, arrhythmia), and no stroke. Subjects could use their regular medication, except β-agonists (short-acting beta agonist for 12 h, long-acting beta agonist for 48 h), and antihistamines for 5 days.

The bronchial challenge was conducted with histamine by a dosimetric method with controlled tidal breathing by use of the Spira Elektro2 jet nebulizer (Respiration Care Centre Ltd., Hämeenlinna, Finland) (30). Subjects inhaled buffered histamine diphosphate aerosol in fourfold increasing doses (0.025 mg, 0.1 mg, 0.4 mg, 1.6 mg) at 5-min intervals. The end-point of the BHR test was either an at least 15% fall in FEV₁ or the maximum noncumulative dose of histamine of 1.6 mg. After the provocation, 0.4 mg of salbutamol (Ventoline, GlaxoSmithKline, Brentford, UK) was given via spacer (Volumatic®; GlaxoSmithKline, London, UK). Post-bronchodilatation FEV₁ was measured 15 min thereafter. PD₁₅FEV₁ value for histamine was calculated by interpolation (31). The dose-response slope (DRS) was calculated as the relationship of the maximum percent decline in FEV₁ and the relevant dose of histamine by the method of O’Connor et al. (32). The challenge test lasted 30 min.

Definitions

Classification of BHR severity in the present study is based on an earlier clinical validation study of the histamine method (30). For the histamine challenge, the following classification criteria for BHR were: severe, PD₁₅FEV₁ ≤ 0.100 mg; moderate, 0.100 < PD₁₅FEV₁ ≤ 0.400 mg; mild, 0.400 < PD₁₅FEV₁ ≤ 1.600 mg; and no BHR, PD₁₅FEV₁ > 1.600 mg.

BHR: histamine PD₁₅FEV₁ ≤ 1.6 mg, the higher cut-off level (in the regression analysis) for abnormal BHR. Includes subjects with severe, moderate or mild BHR (30).
Statistical analyses

Chi-squared and linear-by-linear tests allowed assessment of the effect of demographic categorical variables on the BHR. We determined BHR severity, risk factors and symptoms associated with BHR using two different cut-off levels of PD_{15}FEV_{1}. Binary logistic regression analysis served to assess the correlation between BHR and answers to the questionnaire. Age, gender, family history of asthma and determinants significant in the univariate analysis were included in the multivariate regression analysis. Correlations and logistic regression of DRS were calculated after ln transformation by the formula \(\ln(DRS + 1)\), in which 1 served as a constant in order to avoid negative values of DRS. The representativeness of the present cohort was studied by 95% confidence intervals (CIs).

The programs of SPSS (SPSS for Windows version 15.0; SPSS, Inc., Chicago, IL, USA) and StatXact 8-2007 (Cytel Inc., Cambridge, MA, USA) served for statistical analysis.

Results

Of all the subjects, 78.8% had no BHR. The proportion of subjects with BHR was 21.2% \((n = 62)\) and with BHR\(_{ms}\) 6.2% \((n = 18)\) (Fig. 2).

Prevalence of smoking, allergic sensitization and physician-diagnosed asthma are presented in Table 2. Demographic variables, data of asthma, respiratory symptoms and lung function in relation to BHR are shown in Table 3.

Determinants of BHR

The main determinant for BHR and BHR\(_{ms}\) was decreased FEV\(_1\) (<80% of predicted), odds ratio (OR) 5.39 and 14.26, respectively. The strongest determinant of BHR was FEV\(_1\) < 80% of predicted combined with airway obstruction (FEV\(_1\)/FVC < 88% of predicted) (OR 7.16, 95% CI 2.02–25.32). Reversibility of the airway defined as FEV\(_1\) change after bronchodilatation (ΔFEV\(_1\)) + 12% and ≥0.2 L occurred in four subjects, of whom three had BHR (OR 11.64, 95% CI 1.19–113.98). Wheezing, SOB and nocturnal asthma symptoms were significantly associated with BHR and BHR\(_{ms}\) (Table 3).

Of the 18 subjects with BHR\(_{ms}\) 10 (56%) had baseline FEV\(_1\) below the normal range, of whom 7 also had decreased FEV\(_1\)/FVC (<88% of predicted) with an OR of 42.80 for BHR\(_{ms}\). Ever-smokers were at risk for BHR\(_{ms}\) (OR 5.28).

We found no association of age, gender, body mass index or family history of asthma with BHR. Cold air- or exercise-induced symptoms were not significantly associated with BHR of the magnitude tested. Neither rural living vs urban, childhood conditions, number of siblings, day care before school age, history of eczema nor pets at home were significantly associated with BHR.

Physician-diagnosed asthma was reported by 13 subjects (4.5%), of whom three had FEV\(_1\) < 80% of predicted and nine were ever-smokers. Physician-diagnosed asthma was associated with BHR\(_{ms}\) (OR 5.28).

Only five subjects (1.7%) had used inhaled or cortisone per os on the day of testing. Any physician-prescribed asthma medication ever taken was the response of by 52 subjects (18%), of whom 22 (42%) had used asthma medication during the past 12 months. Any use of inhaled corticosteroids was associated with BHR (OR 6.05) and even to a greater extent with BHR\(_{ms}\) (OR 12.76).

Of the subjects tested, 17 (5.8%) reported asthma or wheezing in childhood; all had a normal FEV\(_1\) (≥80% of predicted), seven subjects (41%) had BHR, three had used asthma medication during the past 12 months, and two had both BHR and physician-diagnosed asthma. Severe respiratory infection before age 5 was associated with BHR (OR 2.32).

Neither atopy nor positive reaction to any single allergen tested correlated with BHR. Atopy combined with obstruction (FEV\(_1\)/FVC < 88% of predicted), however, led to increased risk for BHR (OR 6.32). Multisensitization was associated with BHR\(_{ms}\) (OR 4.67) (Fig. 3), whereas respiratory symptoms of food allergy...
Subjects who took the bronchial provocation test during the pollen season (April–June) showed no difference in reporting rhinoconjunctivitis from those tested outside the pollen season. Those tested during the season, however, were at increased risk for BHR$_{ms}$ (OR 2.70). Of the nonatopic subjects, 30 (23%) reported symptoms of ARC, 28 (21%) had BHR, of whom nine (32%) had BHR$_{ms}$.

### Table 3: Demographic variables, and data for asthma, respiratory symptoms and lung function of the study cohort (n = 292).

Univariate risk factors for bronchial hyperresponsiveness (BHR) by odds ratios (ORs) with 95% confidence intervals (CI) in two different cut-off points for histamine provocative dose inducing a decrease in FEV$_1$ by 15% (PD$_{15}$FEV$_1$) / H$_{11349}$.0.4 mg

| Age | PD$_{15}$ ≤ 1.6 mg, n = 62 | PD$_{15}$ ≤ 0.4 mg, n = 18 |
|-----|----------------------------|---------------------------|
|     | no. (% of 292) | N (% of no.) | OR (95%CI) | no. (% of 292) | N (% of no.) | OR (95%CI) |
| 26 < 41 years | 100 (34.2) | 20 (20.0) | 1 | 5 (5.0) | 1 |
| 41 < 53 years | 96 (32.9) | 18 (18.8) | 0.92 (0.45–1.88) | 2 (2.1) | 0.40 (0.08–2.14) |
| 53–66 years | 96 (32.9) | 24 (25.0) | 1.33 (0.68–2.62) | 11 (11.5) | 2.46 (0.82–7.36) |
| Gender |     |     |     |     |
| Men | 123 (42.1) | 20 (16.3) | 1 | 8 (6.5) | 1 |
| Women | 169 (57.9) | 42 (24.9) | 1.70 (0.94–3.08) | 10 (5.9) | 0.90 (0.35–2.36) |
| BMI |     |     |     |     |
| >30 | 48 (16.4) | 12 (25.0) | 1.29 (0.63–2.67) | 3 (6.3) | 1.02 (0.28–3.66) |
| Ventilatory function* |     |     |     |     |
| FEV$_1$ ≥ 80% of predicted | 259 (88.7) | 45 (17.4) | 1 | 8 (3.1) | 1 |
| FEV$_1$ < 80% of predicted | 32 (11.0) | 17 (53.1) | 5.39 (2.51–11.58) | 10 (31.3) | 14.26 (5.11–39.82) |
| FVC ≥ 80% of predicted | 279 (95.5) | 57 (20.4) | 1 | 18 (6.5) | 0 |
| FVC < 80% of predicted | 12 (4.1) | 5 (41.7) | 2.78 (0.85–9.09) | 0 |
| FEV$_1$/FVC < 88% of predicted | 37 (12.7) | 18 (48.6) | 4.52 (2.20–9.31) | 9 (24.3) | 8.75 (3.21–23.86) |
| FEV$_1$/FVC < 80% of predicted and FEV$_1$/FVC < 88% of predicted | 11 (3.8) | 7 (63.6) | 7.16 (2.02–25.32) | 7 (63.6) | 42.80 (10.89–168.15) |
| Reversibility in FEV$_1$ [ΔFEV$_1$ (L) + 12% and ≥0.2 L] | 4 (1.4) | 3 (75.0) | 11.64 (1.19–113.98) | 1 (25.0) | 5.31 (0.52–53.83) |
| Smoking |     |     |     |     |
| Non-smokers | 121 (41.4) | 19 (15.7) | 1 | 3 (2.5) | 1 |
| Current and ex-smokers | 171 (58.6) | 43 (25.1) | 1.80 (0.99–3.28) | 15 (8.8) | 3.78 (1.07–13.37) |
| Family history of asthma | 53 (18.2) | 14 (26.4) | 1.43 (0.72–2.84) | 4 (7.5) | 1.31 (0.41–4.16) |
| BHR tested in April–June | 83 (28.4) | 19 (22.9) | 1.15 (0.62–2.11) | 9 (10.8) | 2.70 (1.03–7.07) |
| Multisensitization (SPT ≥ 6 allergens)† | 15 (6.0) | 4 (26.7) | 1.42 (0.43–4.67) | 3 (20.0) | 4.67 (1.16–18.78) |
| Severe respiratory infection at age <5 years | 46 (15.8) | 16 (34.8) | 2.32 (1.17–4.61) | 4 (8.7) | 1.58 (0.50–5.03) |
| Physician-diagnosed asthma ever | 13 (4.5) | 5 (38.5) | 2.43 (0.77–7.23) | 3 (23.1) | 5.28 (1.31–21.22) |
| Asthma medication ever | 52 (17.8) | 17 (32.7) | 2.11 (1.08–4.09) | 6 (11.5) | 2.48 (0.89–6.94) |
| Asthma medication (past 12 months) | 22 (7.5) | 11 (50.0) | 4.29 (1.76–10.45) | 4 (18.2) | 4.06 (1.21–13.62) |
| Symptoms |     |     |     |     |
| Ever wheezing | 134 (45.9) | 41 (30.6) | 2.88 (1.60–5.18) | 16 (11.9) | 10.58 (2.39–46.90) |
| Shortness of breath past 12 months | 60 (20.5) | 23 (38.3) | 3.08 (1.65–5.74) | 8 (13.3) | 3.42 (1.29–9.08) |
| Shortness of breath and wheezing in the past 12 months | 17 (5.8) | 13 (76.5) | 14.99 (4.69–47.93) | 4 (23.5) | 5.74 (1.66–19.88) |
| Shortness of breath and wheezing at night | 15 (5.1) | 9 (60.0) | 6.34 (2.16–18.58) | 4 (26.7) | 6.83 (1.93–24.19) |

*FEV$_1$ and FVC values were obtained from 291 subjects. Predicted values according to Viljanen et al. (24).
†SPT done for subjects <61 years of age, n = 251.
BMI, body mass index; FEV$_1$, forced expiratory volume in the first second; FVC, forced vital capacity; SPT, skin-prick test.
Multivariate relationships

The independent determinants for BHRms were FEV₁ < 80% of predicted (OR 27.18), FEV₁/FVC < 88% of predicted (OR 6.16) and use of asthma medication ever (OR 6.72). Whereas risk factors for BHR were decreased FEV₁ (OR 4.09), FEV₁/FVC < 88% of predicted (OR 4.33), history of severe respiratory infection before age 5 (OR 2.65), and reported SOB and wheezing in the past 12 months (OR 13.00) (Table 4).

When multisensitization and obstruction (FEV₁/FVC < 88% of predicted) were analyzed together, they both remained independent risk factors for BHRms (OR 4.68, 95% CI 1.01–21.65 and OR 8.29, 95% CI 2.47–27.81, respectively). These ORs present the same level of increased risk as calculated in univariate analysis.

DRS

LnDRS correlated significantly with BHR and BHRms (Spearman correlation, coefficients 0.664 and 0.415, \( P < 0.001 \) for both), and lnDRS associated significantly with use of asthma medication in the preceding 12 months \( (P = 0.028) \), age \( (P = 0.027) \) and FEV₁ below predicted \( (P = 0.042) \).

Discussion

BHR occurred in 21%, and 6% presented BHRms. The latter is in line with the reported prevalence of physician-diagnosed asthma (7%) in Helsinki (6). We found no discrepancy with results of the European

Table 4. Risk in odds ratios (ORs) with 95% confidence intervals (CI) for histamine provocative dose inducing a decrease in FEV₁ by 15% \( (PD_{15}FEV₁) \leq 1.6 \) and \( PD_{15}FEV₁ \leq 0.4 \) mg, according to multivariate analysis, all subjects \( (n = 292) \) included

|                      | \( PD_{15}FEV₁ \leq 1.6 \) mg | \( PD_{15}FEV₁ \leq 0.4 \) mg |
|----------------------|---------------------------|---------------------------|
| **Age**              |                           |                           |
| 26 < 41 years        | 1                         | 1                         |
| 41 < 53 years        | 0.91 (0.38–2.20)          | 0.67 (0.08–5.40)          |
| 53–66 years          | 1.13 (0.45–2.84)          | 2.79 (0.43–17.94)         |
| **Gender**           |                           |                           |
| Men                  | 1                         | 1                         |
| Women                | 1.87 (0.85–4.10)          | 1.86 (0.35–9.85)          |
| Family history of asthma | 0.96 (0.37–2.48)       | 0.22 (0.02–2.04)          |
| **Ventilatory function** |                        |                           |
| FEV₁ < 80% of predictive | 4.09 (1.45–11.52)       | 27.18 (4.91–150.57)       |
| FEV₁/FVC < 88% of predictive | 4.33 (1.69–11.06)       | 6.16 (1.18–32.21)         |
| Multisensitization (SPT ≤ 6 pos) | 0.81 (0.16–4.07)   | 7.33 (0.69–77.63)         |
| BHR tested in April–June | 0.63 (0.26–1.48)       | 1.00 (0.18–5.58)          |
| **Childhood**        |                           |                           |
| Severe respiratory infection <5 years | 2.65 (1.05–6.70)   | 2.00 (0.25–16.25)         |
| SOB and wheezing in the past 12 months | 13.00 (2.64–63.91) | 2.29 (0.25–20.91)         |
| Asthma medication ever | 1.83 (0.72–4.67)     | 6.72 (1.12–40.53)         |
| **Smoking**          |                           |                           |
| Non-smokers          | 1                         | 1                         |
| Current and ex-smokers | 1.07 (0.48–2.37)       | 1.07 (0.14–8.11)          |

FEV₁, forced expiratory volume in the first second; FVC, forced vital capacity; SOB, shortness of breath; SPT, skin-prick test.
Community Respiratory Health Survey in which the prevalence of BHR ranged from 3% to 28% among 16 countries, with a median prevalence of 13% (34).

We assessed BHR by two cut-off levels of PD_{15}\%FEV_1 indicating different severity levels of BHR, thus showing variations and differences in importance of the determinants assessed. For most of the determinants, ORs were higher, parallel with BHR severity. Our results, however, revealed that some risk factors for BHR and asthma, like severe respiratory infection in childhood, were associated with the higher PD_{15}\%FEV_1 cut-off level only.

The strongest determinant of BHR was decreased FEV_1 (<80% of predicted) when combined with airway obstruction (defined as FEV1/FVC < 88% of predicted). But, studies on the association of BHR with allergic sensitization have yielded a variety of results (35–37). In the present study, atopy only if combined with obstruction in the spirometry led to increased risk for BHR.

Multisensitization independently led to increased risk also for BHR ms. The results on BHR ms agree with findings in experimental studies where the site of obstruction was assessed with synchrotron lung function imaging after methacholine and ovalbumin in sensitized rabbits (38). Provocation with the allergen caused peripheral constriction in the airway different from the more proximal airway constriction caused by intravenous metacholine. However, inhaled methacholine caused a more peripheral bronchoconstriction and a markedly heterogenous ventilation. This finding can, in part, explain our findings with enhanced bronchial responsiveness to inhaled histamine in subjects with decreased FEV_1 and FEV_1/FVC, and with multisensitization.

We found that one out of five nonatopic subjects reported symptoms typical for ARC and also had BHR. In this study, the spring pollen season (April–June), regardless of atopic status, elevates risk for BHR ms, which indicates that some undefined environmental factors are linked with BHR. The airway smooth muscle cells are strongly involved also in noneosinophilic airway inflammation (39). The impact of time and season of testing may explain intrasubject variation in degree of BHR, a fact to consider in clinical use and in treatment strategies.

The present results confirm that smoking is a risk factor for BHR and BHR ms (40). However, in the multivariate analysis, its statistical significance vanished. Further detailed research is needed to assess relation of smoking habits and BHR.

In this study, female gender and BHR showed no association in contrast with some other’s findings (8, 41, 42). The explanation may, at least in part, depend on differences in cohorts’ lung-function values or the use of that data. We used in the analyses spirometric values of predicted, which normalizes the values by gender, age and height. Thus, in this study, we could not assess the gender effect.

The present study has certain limitations mostly because of relatively small number of subjects, slightly below 300. We assessed the representativeness of the present study cohort. The replies concerning the main risk factors for BHR did not reveal discrepancy in the representativeness of the smaller cohort of the present study in comparison with the original study cohort of randomly selected 6062 Helsinki inhabitants.

Because of many differences between study cohorts, such as differences in inclusion criteria and variety of absolute lung volumes, the prevalence of BHR remains arbitrary. Here, 18 subjects (6%) were excluded from BHR measurements because of a low FEV_1 (<60% of predicted), which may underestimate the real magnitude and prevalence of BHR. This fact has received little attention in the interpretation or discussion of any of the BHR general population studies. BHR prevalence studies, as the present investigation, often miss some severe asthma patients because of exclusion criteria by FEV_1, thus diminishing the prevalence of physician-diagnosed asthma in the cohort. Final results will then lack these patients’ data on reported associations, risk factors and determinants of BHR.

The use of asthma medication reduces or abolishes BHR (43). The real influence of medication on the results is difficult to assess in an epidemiologic study setting. We found that asthma diagnosis and medication was associated with BHR, but most of the subjects with BHR ms were those without physician-diagnosed asthma or those without asthma treatment during the past 12 months. We believe that because of the asthma treatment strategies adopted in Finland (33), subjects using asthma medication and with physician-diagnosed asthma were not those who had severe BHR in the present study. In the present cohort, 4.5% of the subjects reported physician-diagnosed asthma, which is in line with the percentage of those receiving special reimbursement of asthma drugs (4.1%) based on chronic asthma in Finland in 2004 (33).

The clinical interview of the present study yielded valuable data from these subjects’ childhoods but offered no simple answer to the question as to use of inhaled corticosteroid treatment for wheezing (44, 45). Our results indicate that in adult subjects with symptoms of asthma in childhood, risk for BHR is higher. Determination of BHR in these subjects with severe...
respiratory symptoms in childhood may be clinically useful when they start to complain about respiratory symptoms in adulthood.

The use of DRS has been suggested for epidemiologic studies in which a majority of those studied show no BHR (46). Here, the results of DRS analysis provided no additional value to results obtained by PD15FEV1.

In this adult general population of Helsinki, 79% of the subjects did not present with BHR (PD15FEV1 > 1.6 mg). This is in line with the high negative value of the histamine PD15FEV1 > 1.6 mg for asthma with the presently used dosimetric histamine method (30, 47). The prevalence of respiratory symptoms among those without BHR seems to be common; the majority of those who reported symptoms were subjects without BHR.

Conclusions

Of the adult population of Helsinki, 21% showed BHR to inhaled histamine. Decreased FEV1 and airway obstruction were the main determinants for BHR. Ever-smoking, multisensitization and the examinations taking place during the pollen season were significantly associated with BHRm, whereas a severe respiratory infection in childhood was associated with generally increased BHR only. Use of asthma medication associated with increased BHR and the prevalence of BHRm were similar to the reported prevalence of physician-diagnosed asthma in Finland. Quantitative assessment of BHR by different cut-off levels provides a tool for characterization of phenotypes of airway disorders in epidemiologic and clinical studies.

Acknowledgements

This part of the FinEss study was supported by The Helsinki University Hospital (Project TYH1235) with grants from the Åland Culture Foundation and Research Foundation for Pulmonary Diseases, Finland. Special thanks to assistants in research Kerstin Ahlskog and Minna Veneranta, to information specialist Tuula Boström, to Carol Norris for language, the staff of the Laboratory of Lung function and Clinical Physiology, and the staff of the Research Center for Lung Diseases in Meilahti Hospital at the Helsinki University Hospitals.

References

1. Woolcock A, Peat J, Salome C, Yan K, Anderson S, Schoeffel R, McCowage G, Killalea T. Prevalence of bronchial hyperresponsiveness and asthma in a rural adult population. Thorax. 1987;42: 361–8.

2. Nowak D, Heinrich J, Jørres R, Wässmer G, Berger J, Beck E, Boczar S, Claussen M, Wichmann H, Magnussen H. Prevalence of respiratory symptoms, bronchial hyperresponsiveness and atopy among adults: West and East Germany. Eur Respir J. 1996;9: 2541–52.

3. Norrman E, Plaschke P, Björnsson E, Resenhall L, Lundbäck B, Jansson C, Lindholm N, Boman G. Prevalence of bronchial hyper-responsiveness in the southern, central and northern parts of Sweden. Respir Med. 1998;92: 480–7.

4. Toelle B, Xuan W, Peat J, Marks G. Childhood factors that predict asthma in young adulthood. Eur Respir J. 2004;23: 66–70.

5. Lundbäck B, Stjernberg N, Rosenhall L, Lindström M, Jönsson E, Andersson S. Methacholine reactivity and asthma. Report from the Northern Sweden Obstructive Lung Disease Project. Allergy. 1993;48: 117–24.

6. Pallasaho P, Lundback B, Läspä S, Jönsson E, Kotaniemi J, Sovijärvi AR, Laitinen LA. Increasing prevalence of asthma but not of chronic bronchitis in Finland? Report from the FinESS-Helsinki study. Respir Med. 1999;93: 798–809.

7. Kotaniemi J, Lundbäck B, Nieminen M, Sovijärvi AR, Laitinen LA. Increase of asthma in adults in Northern Finland? – a report from the FinEss study. Allergy. 2001;56: 169–74.

8. Juusela M, Poussa T, Kotaniemi J, Lundbäck B, Sovijärvi A. Bronchial hyperresponsiveness in a population of North Finland with no previous diagnosis of asthma or chronic bronchitis assessed with histamine and metacholine tests. Int J Circumpolar Health. 2008;67: 308–17.

9. Karjalainen E-M, Laitinen A, Sue-Chu M, Altraja A, Bjermjer L, Laitinen LA. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med. 2000;161: 2086–91.

10. Torchio R, Gulotta C, Ciacco C, Perboni A, Guglielmo M, Crosa F, Zerbini M, Brusasco V, Hyat R, Pellegrino R. Effects of chest wall strapping on mechanical response to metacholine in humans. J Appl Physiol. 2006;101: 430–8.

11. Moreno R, Hogg J, Paré P. Mechanics of airway narrowing. Am Rev Respir Dis. 1986;133: 1171–80.

12. Downie S, Salome C, Verbanck S, Thompson B, Berend N, King G. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. Thorax. 2007;62: 684–9.

13. Tgavelekos N, Musch G, Harris R, Melo M, Winkler T, Schroeder T, Callahan R, Lutchen K, Venegas J. Relationship between airway narrowing, patchy ventilation and lung mechanics in asthmatics. Eur Respir J. 2007;29: 1174–81.

14. Harris S, Winkler T, Tgavelekos N, Musch G, Melo M, Schroeder T, Chang Y, Venegas J. Regional pulmonary perfusion, inflation, and ventilation defects in bronchoconstricted patients with asthma. Am J Respir Crit Care Med. 2006;174: 245–53.
15. Janson C, Chinn S, Jarvis D, Zock J-P, Toren K, Burney P. Effects of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey: a cross-sectional study. Lancet. 2001;358: 2103–9.
16. Chinn S, Jarvis D, Luczynska C, et al. An increase in bronchial responsiveness is associated with continuing or restarting smoking. Am J Respir Crit Care Med. 2005;172: 561–9.
17. Pistelli F, Bottai M, Carrozza L, DiPede F, Baldacci S, Maio S, Brusasco V, Pellegrino R, Viegi G. Changes in obesity status and lung function decline in a general population sample. Respir Med. 2008;102: 674–80.
18. Scichilone N, Messina M, Battaglia S, Catalano F, Bellia V. Airway hyperresponsiveness in the elderly: prevalence and clinical implications. Eur Respir J. 2005;25: 364–75.
19. Brutsche M, Downs S, Schindler C, Gerbase M, Schwartz J, Frey M, Russi E, Ackermann-Liebrich U, Leuenberger P. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax. 2006;61: 671–7.
20. Boutet K, Malo J-L, Ghezzo H, Gautrin D. Airway hyperresponsiveness and risk of chest symptoms in an occupational model. Thorax. 2007;62: 260–4.
21. Chinn S, Schouten JP. Reproducibility of non-specific bronchial challenge in adults: implications for design, analysis and interpretation of clinical and epidemiological studies. Thorax. 2005;60: 395–400.
22. Curjuric I, Zemp E, Dratva J, et al. the SAPALDIA team. Determinants of change in airway reactivity over 11 years in the SAPALDIA population study. Eur Respir J. 2011;37: 497–502.
23. Pallasaho P, Rönmark E, Hahtela T, Sovijärvi A, Lundbæk B. Degree and clinical relevance of sensitization to common allergens among adults: a population study in Helsinki, Finland. Clin Exp Allergy. 2006;36: 503–9.
24. Viljanen AA, Haltunen P, Kreus K-E, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest. 1982;42(Suppl. 159): 5–20.
25. Kainu A. Spirometric studies on the adult general population of Helsinki – bronchodilatation responses, determinants, and intrasession repeatability of FEV1, FEV1/FVC, and forced expiratory time. A report from the FinEsS-Helsinki II study. Dissertation, Helsinki University 2008.
26. Rouhos A. Clinical aspects of exhaled nitric oxide in adults: associations with atopy, bronchial hyperresponsiveness, smoking and chronic obstruction. Dissertation, Helsinki University 2010.
27. Pallasaho P. Prevalence and determinants of respiratory symptoms, asthma, chronic bronchitis and allergic sensitization in Helsinki. A comparison between Finland, Sweden and Estonia. The FinEsS studies – Helsinki I. Dissertation, Helsinki University 2006.
28. Cline MG, Burrows B. Research overview, distribution of allergy in a population sample residing in Tucson, Arizona. Thorax. 1989;44: 425–31.
29. The American Thoracic Society (ATS). Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152: 1107–36.
30. Sovijärvi A, Malmberg P, Reinikainen K, Rytilä P, Poppius H. A rapid dosimetric method with controlled tidal breathing for histamine challenge. Repeatability and distribution of bronchial reactivity in a clinical material. Chest. 1993;104: 164–70.
31. Cockcroft C, Murdock K, Mink J. Determination of histamine PC20; comparison of linear and logarithmic interpolation. Chest. 1983;84: 505–6.
32. O’Connor G, Sparrow D, Taylor D, Segal M, Weiss S. Analysis of dose-response curves to methacholine. Am Rev Respir Dis. 1987;136: 1412–7.
33. Hahtela T, Kaila M, Ahonen E, Kava T, Kninnula T, Mäkelä M, Remes S, Sovijärvi A, Valovirta E. Astman Käypä Hoito – suositus. Duodecim. 2000;1:1: 2568–84. ja päivitys 19.5.2006 s.1–17. [The Finnish Guidelines for Asthma, in Finnish].
34. Chinn S, Burney P, Jarvis D, Luczynska C. Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECHRS). Eur Respir J. 1997;10: 2495–501.
35. Schwartz J, Schindler C, Zemp E, Perruchoud A, Zellweger J-P, Wüthrich B, Leuenberger P, Ackermann-Liebrich U, SAPALDIA Team. Predictors of methacholine responsiveness in a general population. Chest. 2002;122: 812–20.
36. Kerkhof M, Postma D, Schouten J, Monchy J. Allergic sensitisation to indoor and outdoor allergens and relevance to bronchial hyperresponsiveness in younger and older subjects. Allergy. 2003;58: 1261–7.
37. Ekoos H, Rouhos A, Pallasaho P, Karjalainen J, Sarna S, Sovijärvi AR. Equally elevated concentrations of exhaled nitric oxide in nonatopic and low-sensitized atopic asthmatics. Respir Med. 2009;103: 152–8.
38. Bayat S, Strengell S, Porra L, Janosi TZ, Petak F, Suuronen H, Suortti P, Hantos Z, Sovijärvi AR, Habre W. Methacholine and ovalbumin challenges assessed by forced oscillations and synchrotron lung imaging. Am J Respir Crit Care Med. 2009;180: 296–303.
39. Chung KF. Asthma treatments: effects on the airway smooth muscle. In: Chung KF, editor. Airway Smooth Muscle in Asthma and COPD: Biology and Pharmacology. West Sussex; England, John Wiley & Sons, Ltd, 2008: 277–302.
40. Hewitt D. Interpretation of the ‘positive’ methacholine challenge. Am J Ind Med. 2008;51: 769–81.
41. Malo J, Pineau L, Cartier A, Martin R. Reference values of the provocative concentrations of methacholine that cause 6% and 20% changes in forced expiratory volume in one second in a normal population. Am Rev Respir Dis. 1983;128: 8–11.
42. Jögi R, Janson C, Björnsson E, Boman G, Björksten B. Atopy and allergic disorders among adults in Tartu, Estonia compared with Uppsala, Sweden. Clin Exp Allergy. 1998;28: 1072–80.

43. Sovijärvi A, Haahtela T, Ekroos H, Lindqvist A, Saarinen A, Poussa T, Laitinen L. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment. Thorax. 2003;58: 500–4.

44. Jartti T, Lehtinen P, Vanto T, Vuorinen T, Hartiala J, Hiekkinen H, Malmberg P, Mäkelä M, Ruuskanen O. Efficacy of prednisolone in children hospitalized for recurrent wheezing. Pediatr Allergy Immunol. 2007;18: 326–34.

45. Panickar J, Lakhanpaul M, Lambert P, Stephenson T, Smyth A, Grigg J. Oral prednisolone for preschool children with acute virus-induced wheezing. NEJM. 2009;360: 329–38.

46. Sterk P, Fabbri L, Quanjer P, Cockcroft D, O’Byrne P, Anderson S, Juniper E, Malo J. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitising stimuli in adults. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J. 1993;6(Suppl. 16): 53–83.

47. Altman DG, Bland JM. Diagnostic tests2: predictive values. BMJ. 1994;309: 102.